Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-08-08
2006-08-08
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S444000, C514S469000, C548S408000, C549S059000, C549S228000, C549S229000
Reexamination Certificate
active
07087635
ABSTRACT:
The present invention relates to a β3 adrenergic receptor agonist of formula I:or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type 2 diabetes and/or obesity.
REFERENCES:
patent: 4276304 (1981-06-01), Ikezaki et al.
patent: 4826847 (1989-05-01), Michel et al.
patent: 5808080 (1998-09-01), Bell et al.
patent: 5977154 (1999-11-01), Bell et al.
patent: 6011048 (2000-01-01), Mathvink et al.
patent: 6825220 (2004-11-01), Jesudason et al.
patent: 2830884 (1979-01-01), None
patent: 166331 (1986-01-01), None
patent: 221414 (1987-05-01), None
patent: 236624 (1987-09-01), None
patent: 611003 (1994-08-01), None
patent: 678511 (1995-10-01), None
patent: 764640 (1997-03-01), None
patent: 827746 (1998-03-01), None
patent: 159945 (1979-08-01), None
patent: WO 95/29159 (1995-11-01), None
patent: WO 97/10825 (1997-03-01), None
patent: WO 97/46556 (1997-12-01), None
patent: WO 98/4526 (1998-02-01), None
patent: WO 98/9625 (1998-03-01), None
patent: WO 98/32753 (1998-07-01), None
patent: WO 00/40560 (2000-07-01), None
patent: WO 00/44721 (2000-08-01), None
patent: WO 01/7026 (2001-02-01), None
patent: WO 01/35947 (2001-05-01), None
patent: WO 01/36412 (2001-05-01), None
patent: WO 01/53298 (2001-07-01), None
patent: WO 02/6276 (2002-01-01), None
patent: WO 02/38543 (2002-05-01), None
Lee, et al,J. Het. Chem., 32(1):1-11, 1995.
Mathvink,Bioorganic&Medicinal Chemistry Letters, 9(13):1869-1874, 1999.
Shuker, A. J., et al.Tetrahedron Letters; 38(35):6149-6152, 1997.
Weber, et al.,Bioorganic&Medicinal Chemistry Letters;8(9):1101-1106, 1998.
Weber, et al.,Bioorganic&Medicinal Chemistry Letters;8(16):2111-2116, 1998.
Bastian Jolie Anne
Finley Don Richard
He John Xiaoqiang
Jesudason Cynthia Darshini
Ratz Andrew Michael
Chung Susannah L.
Demeter John C.
Eli Lilly and Company
Saeed Kamal A.
Voy Gilbert T.
LandOfFree
3-substituted oxindole β3 agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 3-substituted oxindole β3 agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3-substituted oxindole β3 agonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3716514